FDA's authority over diagnostics became much clearer in 2025, when the U.S. courts held that FDA did not have statutory authority over traditional LDTs, with cleaner separation between CMS and state review of laboratory developed test (LDT) services and FDA review of true in vitro diagnostic tests (IVDs), RUO labeled components and reagents, sample collection kits, and increasingly, diagnostic analysis software.

For IVDs, FDA's longstanding device framework remains the anchor. Companies developing sophisticated assays, including blood-based cancer screening tools, must maintain disciplined alignment between performance claims and FDA authorization.

RUOs and reagents continue to present nuanced compliance challenges. FDA assesses objective intent, how a product is positioned, marketed, and used in practice, not simply the label affixed to the vial or kit. A product labeled "Research Use Only" but marketed in ways that suggest clinical utility may require premarket clearance or approval.

Alternative sample collection kits add another regulatory layer. Novel samples, such as capillary blood or non-standard body fluids, often present device specific limitations such as restrictions on at home use, inclusion in consumer directed kits, and the need for novel analyzers. These are not merely technicalities; they determine what kit combinations and workflows are legally permissible. Companies must ensure that kit design, assembly, and distribution strictly mirror applicable clearances.

The fastest advancing frontier is analytical software, including machine learning models, clinical algorithms, and software as medical device (SaMD) tools undergoing iterative version comparison testing. FDA's evolving public framework for AI and SaMD based products emphasizes lifecycle management, transparency, and the use of predetermined change control plans (PCCPs) to govern post market modifications. The agency has also highlighted the importance of monitoring "real world performance" and detecting issues such as data drift, reinforcing that changes to live algorithms must be pre specified, validated, and tightly controlled.

Importantly, the clinical impact of the intended analyte itself may independently cause software to be regulated as a medical device. When software interprets clinical data, stratifies patient risk, generates individualized recommendations, or automates functions normally performed by clinicians, it can cross the statutory threshold into FDA jurisdiction even if the underlying laboratory test is exempt or subject to enforcement discretion. Dynamic or adaptive algorithms, including those altered through version comparison testing in production environments, pose heightened risk because iterative changes can alter clinical meaning, safety, or performance. In such situations, FDA may require formal validation, robust change control documentation, or a premarket submission before deployment.

Looking ahead, companies should expect greater regulatory emphasis on transparency, algorithm explainability, post market performance monitoring, and more structured boundaries for consumer facing diagnostic models. The greater variety of analytical methods and the increasing complexity/availability of computational analytics means FDA will continue expanding expectations around change control, human oversight, and risk-based governance.